Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review
Abstract
Share and Cite
Velimirovici, M.D.; Feier, C.V.I.; Vonica, R.C.; Faur, A.M.; Muntean, C. Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. Biomedicines 2024, 12, 1291. https://doi.org/10.3390/biomedicines12061291
Velimirovici MD, Feier CVI, Vonica RC, Faur AM, Muntean C. Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. Biomedicines. 2024; 12(6):1291. https://doi.org/10.3390/biomedicines12061291
Chicago/Turabian StyleVelimirovici, Milan Daniel, Catalin Vladut Ionut Feier, Razvan Constantin Vonica, Alaviana Monique Faur, and Calin Muntean. 2024. "Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review" Biomedicines 12, no. 6: 1291. https://doi.org/10.3390/biomedicines12061291
APA StyleVelimirovici, M. D., Feier, C. V. I., Vonica, R. C., Faur, A. M., & Muntean, C. (2024). Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. Biomedicines, 12(6), 1291. https://doi.org/10.3390/biomedicines12061291